Endothelial dysfunction and the metabolic syndrome

Current Diabetes Reports

Volumn 3, Issue 1, 2003, Pages 87-92

  McVeigh, Gary E ^a   Cohn, Jay N ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; GENE INTERACTION; HORMONE ACTION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; OBESITY; PREDICTION; PREVALENCE; REVIEW; RISK ASSESSMENT; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; ARTERIOSCLEROSIS; PATHOPHYSIOLOGY;

ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HUMANS; METABOLIC SYNDROME X; OBESITY; RISK ASSESSMENT;

EID: 0037312230     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0059-0     Document Type: Review

References (50)

1. Zimmet P, Boyko EJ, Collier GR, de Courten M: Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 1999, 892:25-44.
2. Yip J, Facchini FS, Reaven GM: Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998, 83:2773-2776.
3. Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
4. Deprés J-P, Lemieu I, Prud'homme D: Treatment of obesity: need to focus on abdominally obese patients. BMJ 2001, 322:716-720.
5. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
6. Meigs JB: Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000, 152:908-911.
7. Grundy SM: Obesity, metabolic syndrome and coronary atherosclerosis. Circulation 2002, 105:2696-2698.
8. Sakkinen PA, Wahl F, Cushman M, et al.: Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2002, 152:897-907.
9. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
10. Cefalu WT: Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) 2001, 226:13-26.
11. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486-2497.
12. Ford SE, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults. JAMA 2002, 287:356-359.
13. Keys A, Menotti A, Aravanis C, et al.: The seven countries study: 2289 deaths in 15 years. Prev Med 1984, 13:141-154.
14. Wilson PWF, D'Agostino RB, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
15. Rimm EB, Stampfer MJ, Giovannucci E, et al.: Body Size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 1995, 141:1117-1127.
16. Tracy RP: Is visceral adiposity the "enemy within"? Arterioscler Thromb Vasc Biol 2001, 21:881-883.
17. Smiley T, Oh P, Shane LG, et al.: The relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes: a systemic review. Can J Cardiol 2001, 17:797-805.
18. Lemieux I, Pascot A, Prud'homme D, et al.: Elevated C-reactive protein another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001, 21:961-967.
19. Schmidt MI, Duncan BB, Sharett AR, et al.: Markers of inflammation and prediction of diabetes mellitus in adults. (Atherosclerosis Risk In Communities study): a cohort study. Lancet 1999, 353:1649-1652.
20. Das UN: Obesity, metabolic syndrome X and inflammation. Nutrition 2002, 18:430-438.
21. Cermak J, Key N, Bach R, et al.: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82:513-520.
22. Lee RT, Libby P: The unstable atheroma. Arterioscler Thromb Vasc Biol 1997, 17:1859-1867.
23. Blake GJ, Ridker PM: Novel clinical markers of vascular inflammation. Circ Res 2001, 89:763-771.
24. Loskutoff DJ, Samad F: The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol 1998, 18:1-6.
25. Blake GJ, Ridker PM, Kuntz KM: Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol 2002, 40:49-55.
26. Calles-Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001, 22:36-52.
27. Anderson TJ: Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999, 34:631-638.
28. Verma S, Anderson TJ: Fundamentals of endothelial function for the clinical cardiologist. Circulation 2002, 105:546-549.
29. Vallance P, Chan N: Endothelial function and nitric oxide: clinical relevance. Heart 2001, 85:342-350.
30. Lüscher TF, Noll G: Endothelial function as an end-point in international trials: concepts, methods and current data. J Hypertens 1996, 145:S111-S121.
31. Schüchinger Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899-1906.
32. Drexter H: Endothelium as a therapeutic target in heart failure. Circulation 1998, 98:2652-2655.
33. Balletshofer BM, Rittig K, Enderle MD, et al.: Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000, 101:1780-1784.
34. Tounian P, Aggoun Y, Dubern B, et al.: Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study. Lancet 2001, 358:1400-1404.
35. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 1999, 19:972-978.
36. Festa A, D'Agostino R, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome. The insulin resistance atherosclerosis study (IRAS). Circulation 2000, 102:42-47.
37. Cai H, Harrison DG: Endothelial dysfunction and cardiovascular diseases. The role of oxidant stress. Circ Res 2000, 87:840-844.
38. Gopaul NK, Manraj MD, Hebe A, et al.: Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 2001, 44:706-712.
39. Perticone F, Ceravolo R, Candigliota M, et al.: Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 2001, 50:159-165.
40. Vaccarino V, Halford TR, Krumholz HM: Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol 2000, 30:130-138.
41. McVeigh GE, Bratteli CW, Morgan DJ, et al.: Age-related abnormalities in arterial compliance identified by pressure pulse contour analysis. Hypertension 1999, 33:1392-1398.
42. Cohn JN, Finkelstein S, McVeigh GE, et al.: Non-invasive pulse wave analysis for the early detection of vascular disease. Hypertension 1995, 26:503-508.
43. McVeigh GE, Allen PB, Morgan DJ, et al.: Nitric oxide modulation of blood vessel tone identified by arterial waveform analysis. Clin Sci 2001, 100:387-393.
44. Haffner SM, Stern MP, Hazuda HP, et al.: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990, 263:2893-2898.
45. Abate N: Obesity and cardiovascular disease: pathogenic role of the metabolic syndrome and therapeutic implications. J Diabetes Complications 2000, 14:154-174.
46. MacMahon S: Blood pressure and the risk of cardiovascular disease. N Engl J Med 2000, 342:50-51.
47. Grundy SM, Howard B, Smith S Jr, et al.: Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002, 105:2231-2239.
48. McVeigh GE, Hamilton PK, Morgan J: Evaluation of mechanical arterial properties: clinical, experimental and therapeutic aspects. Clin Sci 2002, 102:51-67.
49. Lavrencic A, Guzic Salobir B, Keber I: Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome. Arterioscler Thromb Vasc Biol 2000, 20:551-555.
50. Stühlinger MC, Abbasi F, Chu JW, et al.: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002, 287:1420-1426.